MetaCap

ALX Oncology (ALXO) vs MacroGenics (MGNX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MacroGenics (MGNX) has outperformed ALX Oncology (ALXO) over the past year, gaining 40.0% versus a loss of 25.9%. Over five years, MGNX leads with a -89.6% price change compared with -96.8% for ALXO. ALX Oncology is the larger company by market cap ($137.0 million vs $125.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALXO-25.87%MGNX+40.00%
+261%+105%-52%
Nov 21, 20251 yearNov 20, 2026
ALXO-97.23%MGNX-89.43%
+8%-48%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALXO versus MGNX key metrics
MetricALXOMGNX
Share price$1.06$1.96
Market cap$137.03M$125.26M
1-day change+3.92%-1.01%
YTD return-6.19%+21.74%
1-year return-25.87%+40.00%
5-year return-96.84%-89.56%
EPS (TTM)$-0.87$-2.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$149.50M
Revenue growth (YoY)—-0.31%
Net income (latest FY)$-101.69M$-74.62M
Gross margin—100.00%
Operating margin—-48.72%
Net margin—-49.91%
52-week high$2.66$5.08
52-week low$0.862$1.32
Distance from 52-week high-60.15%-61.42%
Analyst consensusstrong_buybuy
Avg. price target upside+333.96%+308.16%
Average volume1.19M747.02K
Shares outstanding129.27M63.91M
Employees49293
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MGNX has outperformed ALXO by 65.9 percentage points over the past year.

About ALX Oncology

ALXO stock →

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees

About MacroGenics

MGNX stock →

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.

Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees

ALXO vs MGNX FAQ

Which is bigger, ALX Oncology or MacroGenics?

ALX Oncology (ALXO) is larger, with a market capitalization of $137.03M compared with $125.26M for MacroGenics (MGNX).

Which stock has performed better over the past year, ALXO or MGNX?

MGNX returned +40.00% over the past 12 months, compared with -25.87% for ALXO (price return, excluding dividends). Past performance does not predict future results.

Are ALX Oncology and MacroGenics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons